BRAF codon(s) 469 any
Somatic mutations in BRAF have been found in 1–4% of all NSCLC most of which are adenocarcinomas. The G469A mutation results in an amino acid substitution at position 469 in BRAF, occurs within the highly conserved motif of the kinase domain. Most mutant BRAF proteins, such as G469A, have increased kinase activity and are transforming in vitro. In preclinical studies, lung cancer cell lines harboring the BRAF G469A mutation were not sensitive to dasatinib
Sen et al Kinase Impaired BRAF Mutations Confer Lung Cancer Sensitivity to Dasatinib. Sci Transl Med. 2012 May 30; 4(136):
Davies, H., Bignell, G. R., et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.